Abstract
HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Current Gene Therapy
Title: Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF)
Volume: 4 Issue: 2
Author(s): Ryuichi Morishita, Motokuni Aoki, Naotaka Hashiya, Keita Yamasaki, Hitomi Kurinami, Shiro Shimizu, Hirofumi Makino, Yasushi Takesya, Junya Azuma and Toshio Ogihara
Affiliation:
Keywords: angiogenesis, restenosis, gene therapy, peripheral vascular disease, myocardial infarction
Abstract: HGF is a mesenchyme-derived pleiotropic factor, which regulates cell growth, cell motility, and morphogenesis of various types of cells and is thus considered a humoral mediator of epithelial-mesenchymal interactions responsible for morphogenic tissue interactions during embryonic development and organogenesis. Although HGF was originally identified as a potent mitogen for hepatocytes, it has also been identified as a member of angiogenic growth factors. Interestingly, the presence of its specific receptor, c-met, is observed in vascular cells and cardiac myocytes. In addition, among growth factors, the mitogenic action of HGF on human endothelial cells was most potent. Recent studies have demonstrated the potential application of HGF to treat cardiovascular diseases such as peripheral vascular disease, myocardial infarction and cerebrovascular disease. In this review, we will discuss a potential therapeutic strategy using HGF in cardiovascular disease.
Export Options
About this article
Cite this article as:
Morishita Ryuichi, Aoki Motokuni, Hashiya Naotaka, Yamasaki Keita, Kurinami Hitomi, Shimizu Shiro, Makino Hirofumi, Takesya Yasushi, Azuma Junya and Ogihara Toshio, Therapeutic Angiogenesis using Hepatocyte Growth Factor (HGF), Current Gene Therapy 2004; 4 (2) . https://dx.doi.org/10.2174/1566523043346453
DOI https://dx.doi.org/10.2174/1566523043346453 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D Deficiency: Universal Risk Factor for Multifactorial Diseases?
Current Drug Targets Pathophysiology and Pharmacologic Treatment of Venous Thromboembolism
Current Drug Targets Soluble Epoxide Hydrolase Inhibitors and their Potential for Treatment of Multiple Pathologic Conditions
Current Medicinal Chemistry Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Low-Molecular-Weight-Heparins: A Review of Literature
Vascular Disease Prevention (Discontinued) Dietary Patterns and Prevention of Type 2 Diabetes: From Research to Clinical Practice; A Systematic Review
Current Diabetes Reviews Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
Current Drug Targets Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Inflammatory Markers in Hyperlipidemia: From Experimental Models to Clinical Practice
Current Pharmaceutical Design Lipid Disorders in Diabetes Mellitus and Current Management
Current Pharmaceutical Analysis Bone Marrow Microenvironment: A Newly Recognized Target for Diabetes- Induced Cellular Damage
Endocrine, Metabolic & Immune Disorders - Drug Targets A1 Adenosine Receptor Agonists: Medicinal Chemistry and Therapeutic Potential
Current Pharmaceutical Design Apolipoprotein B Antisense Inhibition -Update on Mipomersen
Current Pharmaceutical Design Is Impaired Flow-Mediated Dilatation of the Brachial Artery a Cardiovascular Risk Factor?
Current Vascular Pharmacology Systemic Sclerosis Associated Interstitial Lung Disease
Current Respiratory Medicine Reviews Lithium - Pharmacological and Toxicological Aspects: The Current State of the Art
Current Medicinal Chemistry Inflammatory Mechanisms and Redox Status in Periodontal and Cardiometabolic Diseases: Effects of Adjunctive Nutritional Antioxidants and Statins
Infectious Disorders - Drug Targets Biomedical Imaging in Implantable Drug Delivery Systems
Current Drug Targets Patent Review
Combinatorial Chemistry & High Throughput Screening An Overview of Prospective Drugs for Type 1 and Type 2 Diabetes
Current Drug Targets